Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Summary

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

Lotu Radar provides attributed news summaries and links to the original publisher. Full reporting and copyright remain with the source.